| Prev Close | 7.21 |
| Open | 7.21 |
| Day Low/High | 7.01 / 7.25 |
| 52 Wk Low/High | 0.35 / 3.69 |
| Volume | 12.93K |
| Avg Volume | 28.20K |
Latest News
This Small-Cap Rotation Is Unconvincing
Traders, pressed to find some action, are chasing certain things to a ridiculous extent.
7 Stocks Under $10 Spiking Toward Big Gains
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits
5 Stocks Under $10 Set to Soar Higher
These five stocks trading for less than $10 a share are within range of triggering breakout trades.
A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks
Biotech stocks large and small were plummeting as 2016's painful start began to turn torturous.
3 Stocks Pushing The Drugs Industry Lower
TheStreet highlights 3 stocks pushing the Drugs industry lower today.
Why GenVec (GNVC) Stock Is Up In Aftermarket Trading
Shares of GenVec (GNVC) were up 12.83% to $2.99 in aftermarket trading Thursday.
3 Biotech Stocks Under $10 Triggering Breakouts
Keep an eye on these under-$10 biotech stocks.
GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript
GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Deadline Approaching: The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In GenVec, Inc. Of Class Action Lawsuit And The Deadline Of April 6, 2012 To Seek A Lead Plaintiff Position
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc.
The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In GenVec, Inc. Of Class Action Lawsuit And The Deadline Of April 6, 2012 To Seek A Lead Plaintiff Position
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc.
Law Firm Brower Piven Announces Investigation Of Investor Securities Fraud Against GenVec, Inc.
The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against GenVec, Inc.
GenVec Value Slammed on Drug Failure
The blowup of GenVec's drug for pancreatic cancer in a phase III study reduces fair value to around 30 cents a share.
GenVec, Encorium Group: Early Volume Plays
Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.
10 Biotech Stocks On the Line
Here are ten biotech and drug companies facing upcoming, potentially stock-moving events.
Biotech Calendar: Key Dates for March
March's list of important, potentially stock-moving biotech events
Biotech Stock Mailbag: Rexahn Pharma
In a bonus edition of Mailbag, our biotech columnist answers readers' questions about healthcare stocks and the FDA.
Early Volume Plays: Novavax, GenVec
Several stocks trading near or under $5 were poised to move on above-average volume during Friday's trading session.
10 Biotech Stocks on Clinical Trials Watch
News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months.
Biotech Stock Mailbag: Keryx Biopharmaceuticals
Columnist Adam Feuerstein reports on fan mail, hate mail and readers' queries about Keryx and other biotech stocks.
Conolog, Jackson Hewitt: Late Day Volume Plays
Several stocks trading near $5 were moving on above-average volume during Wednesday's session.
GenVec Financing Sinks Shares: BioBuzz
Offering comes right before data read-out from a crucial cancer drug trial.
Biotech Stock Mailbag: GenVec
Senior columnist Adam Feuerstein responds to readers' biotech stock questions -- and lets Adventrx Pharmaceuticals' CEO sound off in response to a couple recent columns.
Biotech Stock Mailbag Readers' Portfolio
Introducing the Biotech Stock Mailbag Readers' Portfolio, which highlights stocks picked by readers and regularly-updated analysis from columnist Adam Feuerstein.
GenVec, Allied Defense: Early Volume Plays
Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.
On2 Technologies, HealthTronics: Early Volume Plays
Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.
J.P. Morgan Healthcare Confab: Preview
A rundown of what to expect at next week's San Francisco biotech conference.
Delta Petroleum, China Direct: Monday's Volume Plays
Several stocks trading near $5 were moving on above-average volume during Monday's session.
Biotech Stock Mailbag: Cardium Therapeutics
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.